{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T07:42:43Z","timestamp":1708760563769},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s00105-023-05293-5","type":"journal-article","created":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T15:02:15Z","timestamp":1705676535000},"page":"208-213","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Zirkumskripte Sklerodermie im Kindesalter","Juvenile localized scleroderma"],"prefix":"10.1007","volume":"75","author":[{"given":"Timmy","family":"Strauss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"G\u00fcnther","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Normi","family":"Br\u00fcck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,19]]},"reference":[{"key":"5293_CR1","doi-asserted-by":"crossref","unstructured":"Amaral TN, Marques Neto JF, Lapa AT et\u00a0al (2012) Neurologic involvement in scleroderma en coup de sabre. Autoimmune Dis 2012:","DOI":"10.1155\/2012\/719685"},{"key":"5293_CR2","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.3899\/jrheum.081284","volume":"36","author":"T Arkachaisri","year":"2009","unstructured":"Arkachaisri\u00a0T, Vilaiyuk\u00a0S, Li\u00a0S et\u00a0al (2009) The localized scleroderma skin severity index and physician global assessment of disease activity: a\u00a0work in progress toward development of localized scleroderma outcome measures. J\u00a0Rheumatol 36:2819\u20132829","journal-title":"J Rheumatol"},{"key":"5293_CR3","first-page":"213","volume":"48","author":"I Badea","year":"2009","unstructured":"Badea\u00a0I, Taylor\u00a0M, Rosenberg\u00a0A et\u00a0al (2009) Pathogenesis and therapeutic approaches for improved topical treatment in localized scleroderma and systemic sclerosis. Baillieres Clin Rheumatol 48:213\u2013221","journal-title":"Baillieres Clin Rheumatol"},{"key":"5293_CR4","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jaad.2008.05.005","volume":"59","author":"S Christen-Zaech","year":"2008","unstructured":"Christen-Zaech\u00a0S, Hakim\u00a0MD, Afsar\u00a0FS et\u00a0al (2008) Pediatric morphea (localized scleroderma): review of 136 patients. J\u00a0Am Acad Dermatol 59:385\u2013396","journal-title":"J Am Acad Dermatol"},{"key":"5293_CR5","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s00431-018-3144-8","volume":"177","author":"T Constantin","year":"2018","unstructured":"Constantin\u00a0T, Foeldvari\u00a0I, Pain\u00a0CE et\u00a0al (2018) Development of minimum standards of care for juvenile localized scleroderma. Eur J Pediatr 177:961\u2013977","journal-title":"Eur J Pediatr"},{"key":"5293_CR6","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S0190-9622(98)70077-5","volume":"39","author":"BB Cunningham","year":"1998","unstructured":"Cunningham\u00a0BB, Landells\u00a0ID, Langman\u00a0C et\u00a0al (1998) Topical calcipotriene for morphea\/linear scleroderma. J\u00a0Am Acad Dermatol 39:211\u2013215","journal-title":"J Am Acad Dermatol"},{"key":"5293_CR7","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/j.1365-2133.2007.07971.x","volume":"157","author":"M Dytoc","year":"2007","unstructured":"Dytoc\u00a0M, Kossintseva\u00a0I, Ting\u00a0P (2007) First case series on the use of calcipotriol-betamethasone dipropionate for morphoea. Br J Dermatology 157:615\u2013618","journal-title":"Br J Dermatology"},{"key":"5293_CR8","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2174\/18743129014090100030","volume":"9","author":"ID Ferguson","year":"2015","unstructured":"Ferguson\u00a0ID, Weiser\u00a0P, Torok\u00a0KS (2015) A case report of successful treatment of recalcitrant childhood localized scleroderma with infliximab and leflunomide. TORJ 9:30","journal-title":"TORJ"},{"key":"5293_CR9","doi-asserted-by":"publisher","first-page":"135","DOI":"10.4103\/idoj.IDOJ_284_19","volume":"11","author":"R George","year":"2020","unstructured":"George\u00a0R, George\u00a0A, Kumar\u00a0TS (2020) Update on management of morphea (localized scleroderma) in children. Indian Dermatol Online\u00a0J 11:135","journal-title":"Indian Dermatol Online J"},{"key":"5293_CR10","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/j.1600-0625.2012.01475.x","volume":"21","author":"M Ghoreishi","year":"2012","unstructured":"Ghoreishi\u00a0M, Vera Kellet\u00a0C, Dutz\u00a0JP (2012) Type\u00a01 IFN-induced protein MxA and plasmacytoid dendritic cells in lesions of morphea. Exp Dermatol 21:417\u2013419","journal-title":"Exp Dermatol"},{"key":"5293_CR11","doi-asserted-by":"publisher","first-page":"32","DOI":"10.2214\/AJR.07.2163","volume":"190","author":"M Horger","year":"2008","unstructured":"Horger\u00a0M, Fierlbeck\u00a0G, Kuemmerle-Deschner\u00a0J et\u00a0al (2008) MRI findings in deep and generalized morphea (localized scleroderma). AJR Am J Roentgenol 190:32\u201339","journal-title":"AJR Am J Roentgenol"},{"key":"5293_CR12","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/S0889-857X(05)70294-5","volume":"22","author":"SA Jimenez","year":"1996","unstructured":"Jimenez\u00a0SA, Hitraya\u00a0E, Varga\u00a0J (1996) Pathogenesis of scleroderma: collagen. Rheum Dis Clin N Am 22:647\u2013674","journal-title":"Rheum Dis Clin N Am"},{"key":"5293_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11926-015-0506-3","volume":"17","author":"SR Johnson","year":"2015","unstructured":"Johnson\u00a0SR (2015) New ACR EULAR guidelines for systemic sclerosis classification. Curr Rheumatol Rep 17:1\u20138","journal-title":"Curr Rheumatol Rep"},{"key":"5293_CR14","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1001\/archderm.1994.01690050133027","volume":"130","author":"P Joly","year":"1994","unstructured":"Joly\u00a0P, Bamberger\u00a0N, Crickx\u00a0B et\u00a0al (1994) Treatment of severe forms of localized scleroderma with oral corticosteroids: follow-up study on 17\u00a0patients. Arch Dermatol 130:663\u2013664","journal-title":"Arch Dermatol"},{"key":"5293_CR15","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jaad.2013.02.007","volume":"69","author":"CE Kelsey","year":"2013","unstructured":"Kelsey\u00a0CE, Torok\u00a0KS (2013) The localized scleroderma cutaneous assessment tool: responsiveness to change in a\u00a0pediatric clinical population. J\u00a0Am Acad Dermatol 69:214\u2013220","journal-title":"J Am Acad Dermatol"},{"key":"5293_CR16","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1212\/01.wnl.0000334474.88923.e3","volume":"71","author":"I Kister","year":"2008","unstructured":"Kister\u00a0I, Inglese\u00a0M, Laxer\u00a0RM et\u00a0al (2008) Neurologic manifestations of localized scleroderma: a\u00a0case report and literature review. Neurology 71:1538\u20131545","journal-title":"Neurology"},{"key":"5293_CR17","volume-title":"AWMF-Leitlinie Nr. 013\/066 Diagnostik und Therapie der zirkumskripten Sklerodermie","author":"A Kreuter","year":"2023","unstructured":"Kreuter\u00a0A, Moinzadeh\u00a0P, Kinberger\u00a0M et\u00a0al (2023) AWMF-Leitlinie Nr. 013\/066 Diagnostik und Therapie der zirkumskripten Sklerodermie"},{"key":"5293_CR18","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.jaad.2008.07.042","volume":"59","author":"EB Kroft","year":"2008","unstructured":"Kroft\u00a0EB, Berkhof\u00a0NJ, Van De Kerkhof\u00a0PC et\u00a0al (2008) Ultraviolet a phototherapy for sclerotic skin diseases: a\u00a0systematic review. J\u00a0Am Acad Dermatol 59:1017\u20131030","journal-title":"J Am Acad Dermatol"},{"key":"5293_CR19","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2165\/00128071-200910030-00004","volume":"10","author":"EB Kroft","year":"2009","unstructured":"Kroft\u00a0EB, Groeneveld\u00a0TJ, Seyger\u00a0MM et\u00a0al (2009) Efficacy of topical tacrolimus 0.1\u202f% in active plaque morphea: randomized, double-blind, emollient-controlled pilot study. Am J Clin Dermatol 10:181\u2013187","journal-title":"Am J Clin Dermatol"},{"key":"5293_CR20","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1097\/01.bor.0000245727.40630.c3","volume":"18","author":"RM Laxer","year":"2006","unstructured":"Laxer\u00a0RM, Zulian\u00a0F (2006) Localized scleroderma. Curr Opin Rheumatol 18:606\u2013613","journal-title":"Curr Opin Rheumatol"},{"key":"5293_CR21","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1096\/fj.03-1273rev","volume":"18","author":"A Leask","year":"2004","unstructured":"Leask\u00a0A, Abraham\u00a0DJ (2004) TGF\u2011\u03b2 signaling and the fibrotic response. FASEB\u00a0J 18:816\u2013827","journal-title":"FASEB J"},{"key":"5293_CR22","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1001\/archdermatol.2009.79","volume":"145","author":"JJ Leitenberger","year":"2009","unstructured":"Leitenberger\u00a0JJ, Cayce\u00a0RL, Haley\u00a0RW et\u00a0al (2009) Distinct autoimmune syndromes in morphea: a\u00a0review of 245 adult and pediatric cases. Arch Dermatol 145:545\u2013550","journal-title":"Arch Dermatol"},{"key":"5293_CR23","first-page":"757","volume":"65","author":"SC Li","year":"2018","unstructured":"Li\u00a0SC (2018) Scleroderma in children and adolescents: localized scleroderma and systemic sclerosis. Pediatr Clin 65:757\u2013781","journal-title":"Pediatr Clin"},{"key":"5293_CR24","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.autrev.2018.02.004","volume":"17","author":"G Martini","year":"2018","unstructured":"Martini\u00a0G, Fadanelli\u00a0G, Agazzi\u00a0A et\u00a0al (2018) Disease course and long-term outcome of juvenile localized scleroderma: experience from a\u00a0single pediatric rheumatology centre and literature review. Autoimmun Rev 17:727\u2013734","journal-title":"Autoimmun Rev"},{"key":"5293_CR25","first-page":"1410","volume":"48","author":"G Martini","year":"2009","unstructured":"Martini\u00a0G, Ramanan\u00a0AV, Falcini\u00a0F et\u00a0al (2009) Successful treatment of severe or methotrexate-resistant juvenile localized scleroderma with mycophenolate mofetil. Baillieres Clin Rheumatol 48:1410\u20131413","journal-title":"Baillieres Clin Rheumatol"},{"key":"5293_CR26","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/j.1365-2133.2011.10535.x","volume":"166","author":"L Mirsky","year":"2012","unstructured":"Mirsky\u00a0L, Chakkittakandiyil\u00a0A, Laxer\u00a0R et\u00a0al (2012) Relapse after systemic treatment in paediatric morphoea. Br J Dermatology 166:443\u2013445","journal-title":"Br J Dermatology"},{"key":"5293_CR27","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S0889-857X(02)00010-8","volume":"28","author":"KJ Murray","year":"2002","unstructured":"Murray\u00a0KJ, Laxer\u00a0RM (2002) Scleroderma in children and adolescents. Rheum Dis Clin North Am 28:603\u2013624","journal-title":"Rheum Dis Clin North Am"},{"key":"5293_CR28","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1097\/00002281-200211000-00013","volume":"14","author":"JE Pope","year":"2002","unstructured":"Pope\u00a0JE (2002) Scleroderma overlap syndromes. Curr Opin Rheumatol 14:704\u2013710","journal-title":"Curr Opin Rheumatol"},{"key":"5293_CR29","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s00296-019-04269-w","volume":"39","author":"HJ Soh","year":"2019","unstructured":"Soh\u00a0HJ, Samuel\u00a0C, Heaton\u00a0V et\u00a0al (2019) Challenges in the diagnosis and treatment of disabling pansclerotic morphea of childhood: case-based review. Rheumatol Int 39:933\u2013941","journal-title":"Rheumatol Int"},{"key":"5293_CR30","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1111\/j.1346-8138.2008.00552.x","volume":"35","author":"C Stefanaki","year":"2008","unstructured":"Stefanaki\u00a0C, Stefanaki\u00a0K, Kontochristopoulos\u00a0G et\u00a0al (2008) Topical tacrolimus 0.1\u202f% ointment in the treatment of localized scleroderma. An open label clinical and histological study. J\u00a0Dermatol 35:712\u2013718","journal-title":"J Dermatol"},{"key":"5293_CR31","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.jaad.2006.10.959","volume":"56","author":"MM Tollefson","year":"2007","unstructured":"Tollefson\u00a0MM, Witman\u00a0PM (2007) En coup de sabre morphea and parry-romberg syndrome: a\u00a0retrospective review of 54\u00a0patients. J\u00a0Am Acad Dermatol 56:257\u2013263","journal-title":"J Am Acad Dermatol"},{"key":"5293_CR32","first-page":"381","volume":"59","author":"KS Torok","year":"2012","unstructured":"Torok\u00a0KS (2012) Pediatric scleroderma: systemic or localized forms. Pediatr Clin 59:381\u2013405","journal-title":"Pediatr Clin"},{"key":"5293_CR33","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3899\/jrheum.110210","volume":"39","author":"KS Torok","year":"2012","unstructured":"Torok\u00a0KS, Arkachaisri\u00a0T (2012) Methotrexate and corticosteroids in the treatment of localized scleroderma: a\u00a0standardized prospective longitudinal single-center study. J\u00a0Rheumatol 39:286\u2013294","journal-title":"J Rheumatol"},{"key":"5293_CR34","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1111\/j.1600-0560.2009.01201.x","volume":"36","author":"R Walters","year":"2009","unstructured":"Walters\u00a0R, Pulitzer\u00a0M, Kamino\u00a0H (2009) Elastic fiber pattern in scleroderma\/morphea. J\u00a0Cutan Pathol 36:952\u2013957","journal-title":"J Cutan Pathol"},{"key":"5293_CR35","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/j.1365-2133.2008.08647.x","volume":"159","author":"L Weibel","year":"2008","unstructured":"Weibel\u00a0L, Harper\u00a0J (2008) Linear morphoea follows blaschko\u2019s lines. Br J Dermatology 159:175\u2013181","journal-title":"Br J Dermatology"},{"key":"5293_CR36","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1111\/j.1365-2133.2006.07497.x","volume":"155","author":"L Weibel","year":"2006","unstructured":"Weibel\u00a0L, Sampaio\u00a0M, Visentin\u00a0M et\u00a0al (2006) Evaluation of methotrexate and corticosteroids for the treatment of localized scleroderma (morphoea) in children. Br J Dermatology 155:1013\u20131020","journal-title":"Br J Dermatology"},{"key":"5293_CR37","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1177\/1534734607308731","volume":"6","author":"U Wollina","year":"2007","unstructured":"Wollina\u00a0U, Buslau\u00a0M, Heinig\u00a0B et\u00a0al (2007) Disabling pansclerotic morphea of childhood poses a\u00a0high risk of chronic ulceration of the skin and squamous cell carcinoma. Int J Low Extrem Wounds 6:291\u2013298","journal-title":"Int J Low Extrem Wounds"},{"key":"5293_CR38","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/ced.13352","volume":"43","author":"M Yamazaki-Nakashimada","year":"2018","unstructured":"Yamazaki-Nakashimada\u00a0M, Saez-De-Ocariz\u00a0M, Maldonado-Colin\u00a0G et\u00a0al (2018) Subcutaneous immunoglobulin for the treatment of deep morphoea in a\u00a0child. Clin Exp Dermatol 43:303\u2013305","journal-title":"Clin Exp Dermatol"},{"key":"5293_CR39","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1001\/jamadermatol.2018.5040","volume":"155","author":"A Zhang","year":"2019","unstructured":"Zhang\u00a0A, Nocton\u00a0J, Chiu\u00a0Y (2019) A case of pansclerotic morphea treated with tocilizumab. JAMA Dermatol 155:388\u2013389","journal-title":"JAMA Dermatol"},{"key":"5293_CR40","first-page":"614","volume":"45","author":"F Zulian","year":"2006","unstructured":"Zulian\u00a0F, Athreya\u00a0B, Laxer\u00a0R et\u00a0al (2006) Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Baillieres Clin Rheumatol 45:614\u2013620","journal-title":"Baillieres Clin Rheumatol"},{"key":"5293_CR41","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1136\/annrheumdis-2018-214697","volume":"78","author":"F Zulian","year":"2019","unstructured":"Zulian\u00a0F, Culpo\u00a0R, Sperotto\u00a0F et\u00a0al (2019) Consensus-based recommendations for the management of juvenile localised scleroderma. Ann Rheum Dis 78:1019\u20131024","journal-title":"Ann Rheum Dis"},{"key":"5293_CR42","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1002\/art.30264","volume":"63","author":"F Zulian","year":"2011","unstructured":"Zulian\u00a0F, Martini\u00a0G, Vallongo\u00a0C et\u00a0al (2011) Methotrexate treatment in juvenile localized scleroderma: a\u00a0randomized, double-blind, placebo-controlled trial. Arthritis Rheum 63:1998\u20132006","journal-title":"Arthritis Rheum"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-023-05293-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-023-05293-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-023-05293-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T07:02:44Z","timestamp":1708758164000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-023-05293-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,19]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["5293"],"URL":"https:\/\/doi.org\/10.1007\/s00105-023-05293-5","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,19]]},"assertion":[{"value":"22 December 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"T.\u00a0Strauss, C.\u00a0G\u00fcnther und N.\u00a0Br\u00fcck geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. Alle Patient\/-innen, die \u00fcber Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts zu identifizieren sind, haben hierzu ihre schriftliche Einwilligung gegeben.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}